OptiNose AS
1020 Stony Hill Road
Third Floor, Suite 300
Yardley
Pennsylvania
19067
United States
Tel: 267-364-3500
Fax: 267-395-2119
Website: http://www.optinose.com/
Email: info@optinose.com
133 articles about OptiNose AS
-
OptiNose Announces FDA Approval Of XHANCE (Fluticasone Propionate) Nasal Spray For The Treatment Of Nasal Polyps
9/19/2017
-
OptiNose AS Rakes In $37 Million Series D
5/9/2017
-
Michael F. Marino Joins OptiNose AS As Chief Legal Officer
2/9/2017
-
OptiNose AS Announces FDA Acceptance For Filing Of The New Drug Application For OPN-375
1/31/2017
-
OptiNose AS Appoints Keith Goldan As Chief Financial Officer
1/27/2017
-
Tom Gibbs Joins OptiNose AS As Chief Commercial Officer
9/29/2016
-
OptiNose AS Release: New Research Highlights The Burden Of Illness Suffered By Chronic Rhinosinusitis Patients
9/19/2016
-
OptiNose AS Presents Data From Phase III Trials With Investigational Product Using Exhalation Delivery System Technology For Treatment In Patients With Chronic Rhinosinusitis (CRS) With And Without Nasal Polyps
9/16/2016
-
OptiNose AS Announces Pipeline Project To Evaluate Nose-To-Brain Application Of Bi-Directional Breath Powered Technology Selected For Norwegian Government Funding
2/1/2016
-
OptiNose AS Announces FDA Approval For ONZETRA Xsail (Sumatriptan Nasal Powder), A New Treatment For Acute Migraine Using Bi-Directional Breath Powered Technology
1/29/2016
-
OptiNose AS To Present At The 34th Annual J.P. Morgan Healthcare Conference
12/17/2015
-
OptiNose AS Snags $30 Million
10/6/2015
-
OptiNose AS Announces Positive Results Of Second Phase III Pivotal Trial For OPN-375
9/24/2015
-
OptiNose AS Announces Positive Early Phase Clinical Trial With OPN-300, An Investigational Product In Development For Treatment Of Autism Spectrum Disorders
7/15/2015
-
OptiNose AS Announces Positive Results Of Phase III Trial For OPN-375
6/24/2015
-
OptiNose AS To Present At Innovations In Healthcare Executive Forum
3/30/2015
-
OptiNose AS To Present At Nasal And Respiratory Drug Delivery Conferences
3/19/2015
-
OptiNose AS To Present At The 35th Annual Cowen and Company Healthcare Conference
2/23/2015
-
OptiNose AS Announces Publication Of Pivotal Phase 3 Results For Investigational Migraine Treatment Developed By Optinose Using Bi-Directional™ Breath Powered™ Technology
10/31/2014
-
OptiNose AS Completes Series C-1 Financing
8/4/2014